Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes

被引：4

作者：

van der Jagt, Richard ^{[1
]}

机构：

[1] Univ Ottawa, Ottawa Hosp, Ottawa, ON K1H 8L6, Canada

来源：

EXPERT REVIEW OF HEMATOLOGY | 2013年 / 6卷 / 05期

关键词：

bendamustine; follicular lymphoma; indolent; mantle cell lymphoma; non-Hodgkin lymphoma; MANTLE CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; PREVIOUSLY UNTREATED PATIENTS; PROGRESSIVE SOLID TUMORS; PHASE-II MULTICENTER; STUDY-GROUP GLSG; FOLLICULAR LYMPHOMA; B-CELL; PLUS RITUXIMAB; REFRACTORY INDOLENT;

D O I：

10.1586/17474086.2013.841538

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bendamustine is an agent with mostly alkylating properties, which acts on dividing cells through multiple pathways. As an agent with little cross-resistance with other chemotherapeutic agents, bendamustine has received approval for second-line use in relapsed/refractory indolent lymphomas. A growing body of data showing good efficacy and acceptable tolerability of bendamustine in first-line use has led to recognition that this agent has an important role in this setting. This article outlines the pharmacology and clinical studies supporting the use of bendamustine and discusses the role of this agent in the first- and second-line treatment of indolent lymphomas.

引用

页码：525 / 537

页数：13

共 57 条

[1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[2]

[Anonymous], 2013, NCCN Clinical Practice Guidelines in Oncology: Survivorship

[3] Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma [J].

Berenson, James R. ;

Yellin, Ori ;

Bessudo, Alberto ;

Boccia, Ralph V. ;

Noga, Stephen J. ;

Gravenor, Donald S. ;

Patel-Donnelly, Dipti ;

Siegel, Robert S. ;

Kewalramani, Tarun ;

Gorak, Edward J. ;

Nassir, Youram ;

Swift, Regina A. ;

Mayo, Debra .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (03) :321-330

[4] A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) [J].

Blum, Kristie A. ;

Christian, Beth ;

Flynn, Joseph M. ;

Jaglowski, Samantha M. ;

Jones, Jeffrey Alan ;

Maddocks, Kami ;

Byrd, John C. .

BLOOD, 2012, 120 (21)

[5]

Burke JM, 2012, BLOOD, V120

[6] Curability of Advanced Indolent or Low-Grade Follicular Lymphomas: Time for a New Paradigm? [J].

Cabanillas, Fernando .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :14-16

[7]

Cheson BD, 2013, HEMATOL ONCOL S, V1

[8] Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel [J].

Cheson, Bruce D. ;

Wendtner, Clemens-Martin ;

Pieper, Angelika ;

Dreyling, Martin ;

Friedberg, Jonathan ;

Hoelzer, Dieter ;

Moreau, Philippe ;

Gribben, John ;

Knop, Stefan ;

Montillo, Marco ;

Rummel, Mathias .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01) :21-27

[9] Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial [J].

Damaj, Gandhi ;

Gressin, Remy ;

Bouabdallah, Krimo ;

Cartron, Guillaume ;

Choufi, Bachra ;

Gyan, Emmanuel ;

Banos, Anne ;

Jaccard, Arnaud ;

Park, Sophie ;

Tournilhac, Olivier ;

Schiano-de Collela, Jean-Marc ;

Voillat, Laurent ;

Joly, Bertrand ;

Le Gouill, Steven ;

Saad, Alain ;

Cony-Makhoul, Pascale ;

Vilque, Jean-Pierre ;

Sanhes, Laurence ;

Schmidt-Tanguy, Aline ;

Bubenheim, Michael ;

Houot, Roch ;

Diouf, Momar ;

Marolleau, Jean-Pierre ;

Bene, Marie-Christine ;

Martin, Antoine ;

Lamy, Thierry .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :104-110

[10] ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma [J].

Dreyling, M. ;

Thieblemont, C. ;

Gallamini, A. ;

Arcaini, L. ;

Campo, E. ;

Hermine, O. ;

Kluin-Nelemans, J. C. ;

Ladetto, M. ;

Le Gouill, S. ;

Iannitto, E. ;

Pileri, S. ;

Rodriguez, J. ;

Schmitz, N. ;

Wotherspoon, A. ;

Zinzani, P. ;

Zucca, E. .

ANNALS OF ONCOLOGY, 2013, 24 (04) :857-877

← 1 2 3 4 5 6 →